Promising schizophrenia drug faces tough competition
European Pharmaceutical Review
NOVEMBER 25, 2022
According to the pre-IND meeting with the US Food and Drug Administration (FDA), Luye Pharma plans to submit the New Drug Application (NDA) for LY03010 to the FDA through the 505(b)(2) pathway. The post Promising schizophrenia drug faces tough competition appeared first on European Pharmaceutical Review.
Let's personalize your content